Metraipolis › archive › dc_fa427d1411e2
First-Line Chemotherapy Regimens for Advanced and Metastatic Leiomyosarcoma: Doxorubicin vs. Gemcitabine-A Systematic Review — Europe PMC PMID:41595254
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41595254
- DOI
- 10.3390/cancers18020335
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-06T15:29:28.136Z
- SHA-256 of the archived text
6899c4bca25393a488ecff9d70c5b66e543f95613e887094cf98c6b11816b1f1- Stable URL of this page
https://metraipolis.com/documento/dc_fa427d1411e2
How to cite
First-Line Chemotherapy Regimens for Advanced and Metastatic Leiomyosarcoma: Doxorubicin vs. Gemcitabine-A Systematic Review — Europe PMC PMID:41595254 — Europe PMC (en), https://europepmc.org/article/MED/41595254 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_fa427d1411e2 (Metraipolis archive dc_fa427d1411e2, sha256 6899c4bca25393a488ecff9d70c5b66e543f95613e887094cf98c6b11816b1f1)
BibTeX
@misc{dcfa427d1411e2,
title = {First-Line Chemotherapy Regimens for Advanced and Metastatic Leiomyosarcoma: Doxorubicin vs. Gemcitabine-A Systematic Review — Europe PMC PMID:41595254},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41595254},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_fa427d1411e2; sha256 6899c4bca25393a488ecff9d70c5b66e543f95613e887094cf98c6b11816b1f1},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41595254. Agents can read the archived copy with the MCP tool read_document.